ABCL
Abcellera Biologics Inc
12.00$
-6.3%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 112.3% | 99.2% | 68.0% | 519.4% | 588.5% | 275.3% | 1,003.4% | 41.3% | – | 17.7% | 104.1% | – | – | |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 82.3% | -4.1% | 100.0% | 75.0% | |
| 574.6% | 529.7% | 394.7% | 558.9% | 629.6% | 912.4% | 1,003.4% | 229.5% | 614.5% | 111.7% | 561.2% | 1,135.5% | 298.9% | |
| 217.7% | 174.0% | 174.3% | 275.7% | 294.3% | 317.2% | 383.1% | 111.1% | 246.3% | 127.7% | 148.3% | 342.0% | 159.4% | |
| 931.8% | 819.6% | 651.5% | 1,376.2% | 1,539.4% | 1,540.7% | 1,579.6% | 390.2% | 951.8% | 146.1% | 687.7% | 1,650.0% | 415.2% | |
| -831.8% | -719.6% | -551.5% | -1,276.2% | -1,439.4% | -1,440.7% | -1,479.6% | -290.2% | -851.8% | -63.7% | -691.7% | -1,550.0% | -340.3% | |
| – | 182.2% | – | – | – | – | 190.1% | – | – | 35.9% | – | 1.0% | – | |
| -595.2% | -529.5% | -429.4% | -658.0% | -962.5% | -927.3% | -1,251.1% | -212.7% | -767.9% | -43.5% | -595.8% | -1,455.9% | -297.4% | |
| -161.6% | -15.8% | -21.5% | -153.7% | -177.1% | -249.9% | -173.9% | -9.5% | -130.1% | -23.5% | -76.6% | -87.4% | -48.5% | |
| -433.6% | -513.7% | -408.0% | -504.3% | -785.4% | -677.4% | -1,077.2% | -203.3% | -637.8% | -19.9% | -519.1% | -1,368.6% | -248.8% | |
| -676.7% | -583.6% | -450.6% | -711.6% | -797.2% | -1,095.3% | -1,225.5% | -227.3% | -740.5% | -25.8% | -491.7% | -1,025.4% | -242.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.